Technical Analysis for BCRX - BioCryst Pharmaceuticals, Inc.
|Grade||Last Price||% Change||Price Change|
BCRX closed up 1.26 percent on Thursday, April 27, 2017, on 56 percent of normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
Earnings due: May 4
Trend Table & Recent Alerts
|See historical BCRX trend table...|
|Date||Alert Name||Type||% Chg|
|Apr 27||New Downtrend||Bearish||0.00%|
|Apr 24||Stochastic Buy Signal||Bullish||-1.08%|
|Apr 20||NR7||Range Contraction||-3.03%|
|Apr 20||NR7-2||Range Contraction||-3.03%|
|Apr 19||NR7||Range Contraction||-3.17%|
|Apr 18||180 Bearish Setup||Bearish Swing Setup||-3.90%|
|Apr 13||NR7||Range Contraction||-5.04%|
|Apr 13||Stochastic Buy Signal||Bullish||-5.04%|
|Apr 13||Lower Bollinger Band Walk||Other||-5.04%|
|Apr 12||Lower Bollinger Band Walk||Other||-5.87%|
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio.
BioCryst Pharmaceuticals, Inc., a biotechnology company, designs, optimizes, and develops novel drugs that block key enzymes involved in the pathogenesis of diseases. The company integrates the disciplines of biology, crystallography, medicinal chemistry, and computer modeling to discover and develop small molecule pharmaceuticals through the structure-guided drug design process. Its product candidates include peramivir, an intravenous neuraminidase inhibitor, which is approved for seasonal influenza in Japan and Korea, as well as in Phase III clinical trials for acute influenza; ulodesine, an oral purine nucleoside phosphorylase inhibitor, which has completed Phase II clinical trials for the treatment of gout; and forodesine, an oral purine nucleoside phosphorylase inhibitor that is in Phase II clinical trials for oncology. The companys product candidates also comprise BCX4161, a Phase I oral serine protease inhibitor for kallikrein hereditary angioedema; and BCX4430, a preclinical, RNA dependent-RNA polymerase inhibitor for treating Filoviruses. It has collaborative relationships with Mundipharma International Holdings Limited for the development and commercialization of forodesine; and Shionogi & Co., Ltd. and Green Cross Corporation for the development and commercialization of peramivir. Biocryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
Is BCRX a Buy, Sell or Hold?
|Indicator||Bull Case||Neutral / Hold||Bear Case|
|Oversold / Overbought|
|Summary:||Counts: 1 bullish, 3 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.|
See more BCRX news...
|52 Week High||9.25|
|52 Week Low||2.49|
|200-Day Moving Average||5.5972|
|50-Day Moving Average||7.4552|
|20-Day Moving Average||7.1258|
|10-Day Moving Average||6.583|
|Average True Range||0.3606|
|Chandelier Exit (Long, 3 ATRs)||7.9082|
|Chandelier Exit (Short, 3 ATRs)||7.3318|
|Upper Bollinger Band||8.4958|
|Lower Bollinger Band||5.7558|
|Percent B (%b)||0.24|